Log in
Enquire now
‌

US Patent 10253091 Antibody constant region variant

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
102530910
Patent Inventor Names
Hirotake Shiraiwa0
Atsuhiko Maeda0
Taichi Kuramochi0
Tomoyuki Igawa0
Date of Patent
April 9, 2019
0
Patent Application Number
146802500
Date Filed
April 7, 2015
0
Patent Citations
‌
US Patent 10011858 Methods for producing polypeptides by regulating polypeptide association
0
‌
US Patent 10066018 Antibody constant region variant
Patent Citations Received
‌
US Patent 12122840 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
0
‌
US Patent 11248053 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
‌
US Patent 11649262 Method for promoting efficiency of purification of Fc region-containing polypeptide
0
‌
US Patent 11332533 Modified antibody constant region
‌
US Patent 11780908 Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
‌
US Patent 11851486 Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
0
‌
US Patent 11891432 Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
0
‌
US Patent 12116414 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
0
...
Patent Primary Examiner
‌
Lynn A Bristol
0
Patent abstract

By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10253091 Antibody constant region variant

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.